The firm's Phase I/II study yielded responses in mCRPC patients with androgen receptor mutations but it wasn't as promising in HR-positive breast cancer.

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as demonstrated by the PRESTO, EMBARK, and ENZARAD trials. The PRESTO trial ...

Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals has provided an update on its ProstACT Global Phase 3 study ...

IsoPSA is a blood assay that detects variations of the PSA protein that signal a higher likelihood of high-grade tumors. It ...

Prostate cancer is one of the most common cancers affecting men, especially over the age of 50. As per the American Cancer ...

If you have prostate cancer you must consider certain points that will help you get the best treatment Read this article to ...

New findings suggest blood tests still being assessed are showing promising results for early cancer screenings, especially ...

Statistics show a clear spike in eight cancers in younger people, but that has brought a debate over whether many cases ever ...

If you’re dealing with advanced prostate cancer, the thought of surgery might feel like a lot to take in — and that’s completely understandable. For many men facing an advanced diagnosis, surgery will ...